{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:12:12Z","timestamp":1791807132177,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40291-024-00719-9","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T13:02:26Z","timestamp":1716469346000},"page":"495-499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Talicabtagene Autoleucel: First Approval"],"prefix":"10.1007","volume":"28","author":[{"given":"Tina","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"719_CR1","unstructured":"Laurus Labs. ImmunoACT announces the approval of India\u2019s first CAR-T cell therapy, NexCAR19 (actalycabtagene autoleucel), for the treatment of r\/r B-cell lymphomas and leukemia from the Central Drugs Standard Control Organization (CDSCO) [media release]. 13 Oct 2023. https:\/\/www.lauruslabs.com\/."},{"issue":"1","key":"719_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022;46(1):100826.","journal-title":"Curr Probl Cancer"},{"key":"719_CR3","volume-title":"Actalycabtagene autoleucel (NexCAR19): Indian prescribing information","author":"Immunoadoptive Cell Therapy Pvt Ltd","year":"2023","unstructured":"Immunoadoptive Cell Therapy Pvt Ltd. Actalycabtagene autoleucel (NexCAR19): Indian prescribing information. Mumbai: Immunoadoptive Cell Therapy Pvt Ltd; 2023."},{"issue":"4","key":"719_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.tracli.2023.05.001","volume":"30","author":"T Kumar Suvvari","year":"2023","unstructured":"Kumar Suvvari T, Suresh V, Patel K, et al. CAR-T cell therapy in India: challenges and opportunities for advancement. Transfus Clin Biol. 2023;30(4):373\u20135.","journal-title":"Transfus Clin Biol"},{"issue":"5","key":"719_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/1535-7163.MCT-20-0476","volume":"20","author":"A Dwivedi","year":"2021","unstructured":"Dwivedi A, Karulkar A, Ghosh S, et al. Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells. Mol Cancer Ther. 2021;20(5):846\u201358.","journal-title":"Mol Cancer Ther"},{"issue":"8005","key":"719_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","volume":"627","author":"S Mallapaty","year":"2024","unstructured":"Mallapaty S. Cutting-edge CAR-T cancer therapy is now made in India \u2014 at one-tenth the cost. Nature. 2024;627(8005):709\u201310.","journal-title":"Nature"},{"key":"719_CR7","unstructured":"Clinical Trials Registry India. Clinical Trials Registry India identifier CTRI\/2023\/03\/050689. 2023. http:\/\/ctri.nic.in. Accessed 16 May 2024."},{"key":"719_CR8","unstructured":"Viswanath Pilla. Seeking technology, manufacturing partnership with Indian pharma companies, says Mexico foreign secretary [media release]. 08 Mar 2023. https:\/\/economictimes.indiatimes.com\/."},{"key":"719_CR9","unstructured":"ImmunoACT. About us - innovation partners. 2023. https:\/\/www.immunoact.com\/. Accessed 16 May 2024."},{"key":"719_CR10","unstructured":"eHealth Network. Boost for cancer care in India: Tata Memorial Hospital, IIT Bombay conduct first CAR-T cell therapy in early phase pilot clinical trial [media release]. 9 Jun 2021. https:\/\/ehealth.eletsonline.com\/."},{"key":"719_CR11","unstructured":"Laurus Labs. Laurus Labs further invests in cell and gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction [media release]. 31 May 2023. https:\/\/www.lauruslabs.com\/."},{"key":"719_CR12","unstructured":"Viswanath Pilla. Laurus Labs to buy 26% in CAR T-cell therapy company [media release]. 20 Nov 2021. https:\/\/economictimes.indiatimes.com\/."},{"key":"719_CR13","unstructured":"ImmunoACT. Products - our product pipeline. 2023. https:\/\/www.immunoact.com\/. Accessed 16 May 2024."},{"key":"719_CR14","unstructured":"World Intellectual Property Organization. Novel humanized anti-CD19 chimeric antigen receptor, its nucelic acid sequence and its preparation (WO2019159193A1). 2019. https:\/\/patents.google.com\/. Accessed 16 May 2024."},{"issue":"1","key":"719_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41587-023-02049-3","volume":"42","author":"B Johnson","year":"2024","unstructured":"Johnson B. Reducing the costs of blockbuster gene and cell therapies in the Global South. Nat Biotechnol. 2024;42(1):8\u201312.","journal-title":"Nat Biotechnol"},{"key":"719_CR16","doi-asserted-by":"crossref","unstructured":"Jain H, Karulkar A, Kalra D, et al. High efficacy and excellent safety profile of actalycabtagene autoleucel, a humanized CD19 CAR-T product in r\/r B-cell malignancies: a phase II pivotal trial [abstract plus poster]. In: American Society of Hematology Annual Meeting. 2023.","DOI":"10.1182\/blood-2023-185507"},{"key":"719_CR17","unstructured":"Clinical Trials Registry India. Clinical Trials Registry India identifier CTRI\/2021\/04\/032727. 2022. http:\/\/ctri.nic.in. Accessed 16 May 2024."},{"issue":"Suppl 1","key":"719_CR18","doi-asserted-by":"publisher","first-page":"6878","DOI":"10.1182\/blood-2023-180867","volume":"142","author":"G Narula","year":"2023","unstructured":"Narula G, Keerthivasagam S, Jain H, et al. Evaluating the safety of HCAR19 (now actalycabtagene autoleucel- Actaly-cel\u2122), a novel humanized CD19-directed chimeric antigen receptor T-cells in pediatric, adolescents, and young adults with relapsed\/refractory B- acute lymphoblastic leukemia (ESHA) - report of phase-1B [abstract]. Blood. 2023;142(Suppl 1):6878\u201380.","journal-title":"Blood"},{"issue":"Suppl 1","key":"719_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2023-177594","volume":"142","author":"A Karulkar","year":"2023","unstructured":"Karulkar A, Jaiswal AK, Khan A, et al. Excellent safety profile of a low-cost novel humanized CD19 CAR T-cell therapy, actalycabtagene autoleucel\u202f: potential impact on access and feasibility [abstract]. Blood. 2023;142(Suppl 1):257\u20139.","journal-title":"Blood"},{"issue":"Suppl 1","key":"719_CR20","doi-asserted-by":"publisher","first-page":"10332","DOI":"10.1182\/blood-2022-166082","volume":"140","author":"H Jain","year":"2022","unstructured":"Jain H, Karulkar A, Sharma N, et al. Phase I trial of humanized CD19 CART-cell therapy developed in India: safe, active and feasible for outpatient therapy [abstract]. Blood. 2022;140(Suppl 1):10332\u20134.","journal-title":"Blood"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00719-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:04:40Z","timestamp":1719482680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00719-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00719-9","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Tina Nie is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}